Shots: The approval is based on P-II GEOMETRY mono-1 study assessing Tabrecta (400mg, bid) in 97 patients with metastatic NSCLC harboring mutations that lead to METex14. The US FDA approved the […]readmore
Tags : Capmatinib
Shots: The US FDA has accepted NDA and granted PR designation to Capmatinib as a 1L treatment for LA/m- MET exon 14 skipping (METex14) mutated NSCLC The NDA submission is […]readmore
Pharma
Regulatory
Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation
Shots: The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology The BT […]readmore
Shots: The P-II GEOMETRY mono-1 study results involves assessing of Capmatinib (400mg, bid) in 97 treatment-naive & prior treated patients with LA/metastatic NSCLC harboring a MET exon-14 skipping mutation The […]readmore